Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05555862 · ClinicalTrials.gov registry record · Phase 2
Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL
A Phase 2 study of HPV Infection and Anal Dysplasia, sponsored by Frantz Viral Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
- 2
- Study locations
NCT05555862 is a Phase 2 study of HPV Infection and Anal Dysplasia that is active but no longer recruiting, run by Frantz Viral Therapeutics. The registered enrollment target is 17 participants, below the 235-participant average among 13 other HPV Infection trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05555862, a Phase 2 study of HPV Infection and Anal Dysplasia, is active but no longer recruiting, sponsored by Frantz Viral Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a phase II double blind, placebo-controlled, randomized study of Artesunate suppositories for the treatment of HIV-negative men and women who have anal high grade squamous intraepithelial lesions (anal HSIL)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Artesunate
Study Locations (2)
Illinois
- Anal Dysplasia Clinic MidWest - Chicago
New York
- Laser Surgery Care - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2023-02-10 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05555862
The ClinicalTrials.gov registry entry for NCT05555862 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 235-participant average among 13 other HPV Infection trials with a reported enrollment target (93% lower). The listed sponsor is Frantz Viral Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with HPV Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05555862 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT05555862 about?
NCT05555862 is a clinical study titled "Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL". This is a phase II double blind, placebo-controlled, randomized study of Artesunate suppositories for the treatment of HIV-negative men and women who have anal high grade squamous intraepithelial lesions (anal HSIL)
What is the current status of trial NCT05555862?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2023-02-10. Estimated completion is 2026-12-31.
What conditions does trial NCT05555862 study?
This clinical trial studies the following conditions: HPV Infection, Anal Dysplasia, Anal High-grade Squamous Intraepithelial Lesion, HPV Disease, Anal Precancerous Condition.
What interventions are being tested in trial NCT05555862?
The interventions under investigation include: Placebo (DRUG), Artesunate (DRUG).
Who is sponsoring clinical trial NCT05555862?
This trial is sponsored by Frantz Viral Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05555862 being conducted?
This trial has 2 study locations across Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HPV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)
RECRUITING · Phase 2
-
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
RECRUITING · Phase 2
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
PCOM2 - The Physician Communication Intervention, Version 2.0
RECRUITING · NA
-
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
RECRUITING · Phase 4
-
Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.